PROM1 and neoplasm: Studies have also reported the potential therapeutic use of ATRA in NSCLC, both in vitro and in vivo[55], [56], [57], in addition to the targeting of cisplatin-induced enrichment of CD133+ tumour initiating cells within the cancer stem cell compartment [38].